Thursday, July 24, 2014 Last update: 6:03 AM
FreshNews.com - All Company Technology News Since 1996

Sanaria Inc. to launch crowdfunding campaign for SporoBotTM, a mosquito-dissecting robot for accelerating manufacture of Sanaria's malaria vaccine.

Companies mentioned in this article: Sanaria Inc.

ROCKVILLE, Md., April 29, 2014 /PRNewswire-USNewswire/ -- Biotechnology company Sanaria Inc.( )aims to raise at least $250,000 in 30 days on Indiegogo.com, a crowdfunding website. The campaign launches on May 6, 2014. Funds will be dedicated to the development of SporoBot(TM), a robot that will dissect mosquito salivary glands. By replacing manual microdissection of mosquito salivary glands, Sporobot(TM) will automate a key step in the manufacturing process of Sanaria(®) PfSPZ Vaccine against malaria.

In a recent phase 1 clinical trial Sanaria(®) PfSPZ Vaccine fully protected against malaria all volunteers who received the highest administered dose. This is the first malaria vaccine ever to show such efficacy. Based on these exciting results reported in Science magazine in 2013, Sanaria(®) PfSPZ Vaccine is being assessed in clinical trials in the USA (3 sites), Mali, Tanzania, Equatorial Guinea, and Germany in 2014.

"The individual components of the robot work. Now we must determine how to successfully put them together to create the prototype of SporoBot(TM), a robot to mass-produce the vaccine faster at a lower cost," says Stephen L. Hoffman, MD, CEO and founder of Sanaria. "This will allow us to provide the vaccine sooner and at less expense to the hundreds of millions of people who suffer from malaria each year, are most in need of protection and can least afford health care."

There is no time to lose. More than 600,000 people die from malaria each year. More than 1,000 children die of the disease every day. To integrate SporoBot(TM) into the vaccine manufacturing process, Sanaria needs to build a prototype that meets standards of efficiency and consistency, is operational under the guidelines of pharmaceutical manufacturing, is compatible with downstream processing, and is robust enough for continuous manufacturing.

"This campaign is about working together with supporters of large and small means to make progress toward finally ending one of the world's deadliest diseases," stated Hoffman. "Crowdfunding provides an opportunity for everyone to participate in the development of a potentially game-changing technology to help those most in need."

More information can be found at endofmalaria.com and at Indiegogo.

About Sanaria Inc.: ?Sanaria Inc. was founded in 2003. The Company's mission is to develop and commercialize whole-parasite malaria vaccines that confer high-level, long-lasting protection against Plasmodium falciparum, the parasite responsible for most of the malaria-associated severe illness and death worldwide, and the other parasites that cause human malaria, and to use these vaccines to eliminate malaria. Sanaria's corporate headquarters, administrative, research, development, and manufacturing operations are located in Rockville, Maryland. The Company's website is sanaria.com. Except for historical information, this news release contains certain forward-looking statements that involve known and unknown risk and uncertainties, which may cause actual results to differ materially from any future results, performance or achievements expressed or implied by the statements made. Such statements include the availability of an effective vaccine, the expectations for conquering malaria, beliefs concerning the suitability of a successful vaccine, and the establishment of a path toward prevention of infection. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the Company's ability to raise sufficient funds, the regulatory approval process, dependence on third parties, clinical trials results, the Company's patent portfolio, ability to commercialize the vaccine, dependence on key personnel and other risks associated with vaccine development. For further information about Sporobot(TM) contact sporobot@sanaria.com. For information about Sanaria contact Adam Richman at arichman@sanaria.com or Robert Thompson at 240-403-2750.

SOURCE Sanaria Inc.